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6(E),8(Z),11(Z),14(Z)‑eicosatetraenoic Acid
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and Theodore R. Holman*,†
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ABSTRACT: 5-Lipoxygenase (5-LOX) reacts with arachidonic acid
(AA) to first generate 5(S)-hydroperoxy-6(E),8(Z),11(Z),14(Z)-eicosa-
tetraenoic acid [5(S)-HpETE] and then an epoxide from 5(S)-HpETE
to form leukotriene A4, from a single polyunsaturated fatty acid. This
work investigates the kinetic mechanism of these two processes and the
role of ATP in their activation. Specifically, it was determined that
epoxidation of 5(S)-HpETE (dehydration of the hydroperoxide) has a
rate of substrate capture (Vmax/Km) significantly lower than that of AA
hydroperoxidation (oxidation of AA to form the hydroperoxide);
however, hyperbolic kinetic parameters for ATP activation indicate a
similar activation for AA and 5(S)-HpETE. Solvent isotope effect results
for both hydroperoxidation and epoxidation indicate that a specific step
in its molecular mechanism is changed, possibly because of a lowering of
the dependence of the rate-limiting step on hydrogen atom abstraction and an increase in the dependency on hydrogen bond
rearrangement. Therefore, changes in ATP concentration in the cell could affect the production of 5-LOX products, such as
leukotrienes and lipoxins, and thus have wide implications for the regulation of cellular inflammation.
Human 5-lipoxygenase (5-LOX) is a non-heme iron-containing enzyme responsible for catalyzing the stereo-
specific and regiospecific peroxidation of natural polyunsatu-
rated fatty acid (PUFA) substrates, specifically converting
arachidonic acid (AA) into 5(S)-hydroperoxy-6-trans-8,11,14-
cis-eicosatetraenoic acid [5(S)-HpETE].1,2 5-LOX shares this
hydroperoxidation activity with other lipoxygenases, such as 12-
LOX and 15-LOX, although these generate different products
with different biological roles in the cell [e.g., 12(S)-HpETE
and 15(S)-HpETE, respectively]. A unique feature of 5-LOX is
the additional catalytic step of converting 5(S)-HpETE into the
epoxide, leukotriene A4 (LTA4) (Figure 1). This biomolecule is
the first in a line of highly pro-inflammatory mediators that act
as potent chemoattractants and are implicated in a variety of
diseases from asthma to cancer.3−6 Distinguishing the biological
role of 5-LOX further is the fact that LTA4 can also be shuttled
into neighboring cells expressing 12- and 15-LOX via
mechanisms of transcellular biosynthesis.7,8 Ultimately, LTA4
is converted to a series of inflammatory biomolecules (e.g.,
leukotrienes and lipoxins), both of which are important in
initiating and terminating inflammation.9,10
5-LOX catalytic activity is regulated through several
mechanisms by the cell. 5-LOX is recruited to the nuclear
membrane upon cellular Ca2+ influx. Calcium binds to allosteric
sites in the 5-LOX N-terminal polycystin-1/lipoxygenase/α-
toxin (PLAT) domain, promoting attachment to the membrane
via conserved tryptophan residues that embed into the lipid
bilayer.11−13 There is also evidence that magnesium can
substitute for calcium in this regard.14 Membrane association
leads to an increased level of production of hydroperoxide and
leukotriene.15,16 5-LOX must interact with 5-LOX-activating
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Figure 1. Important metabolites of the regulation of inflammation
made by 5-LOX with AA.
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protein (FLAP) to secure PUFA substrates from the nuclear
membrane and further promote leukotriene formation in
vivo.17,18 Evidence of an additional protein−protein interaction
with coactosin-like protein (CLP), an actin binding protein,
suggests CLP helps stabilize the membrane-docked 5-LOX and
enhances leukotriene formation 3-fold.19,20 The fate of LTA4
depends on where 5-LOX is localized in the cell when it is
activated to bind the nuclear membrane, a phenomenon termed
compartmentalization.21−23 LTA4 can be converted to LTB4 by
LTA4 hydrolase, a soluble protein that can localize in the
nucleus, or to LTC4 by LTC4 synthase, a membrane-bound
protein embedded in the outer leaflet of the nuclear membrane.
Compartmentalization implicates the importance of the 5-LOX
nuclear localization sequences,24 which may be further
regulated by phosphorylation.25 Lastly, the ability of 5-LOX
to dimerize may provide yet another avenue of enzymatic
regulation.26
In addition to the calcium binding allosteric sites, there is an
ATP binding site(s) that contributes to 5-LOX activation.27−29
Previous studies report a range of 5-LOX activating potentials,
from a 5-fold increase in 5-LOX activity27 to a 25-fold increase
in kcat/Km with Ca
2+ added,30 both found in guinea pig
peritoneal polymorphonuclear leukocytes (PMNLs). Further-
more, the substrate specificity of 5-LOX is affected by ATP,
with the kcat/Km ratio of AA to eicosapentaenoic acid (EPA)
increasing 2-fold.30 Unfortunately, the ATP-induced activation
mechanism is not thoroughly understood and is often explained
with generalized statements, such as extending enzyme
stability.31 The recent crystal structure of Stable-5-LOX, a
mutant with a half-life longer than that of wild-type 5-LOX,
gave further impetus for characterizing ATP’s effect on 5-LOX
because the structural determinants for ATP-induced activation
were not obvious from the structure.32 In addition, it was not
known if ATP activated just hydroperoxidation or epoxidation
as well.
In comparing the proposed mechanisms of hydroperox-
idation (oxidation of AA) and epoxidation (dehydration of the
hydroperoxide to form the epoxide), we observed that they are
similar but exhibit four key differences (Figure 2). First, the
hydrogen atom is abstracted from C7 for hydroperoxidation
but from C10 for epoxidation. Therefore, the positioning of the
substrate will be distinct between the two processes because the
Fe(III)−OH moiety is proposed to be the active species for
both abstractions. Second, molecular oxygen does not attack
the radical intermediate for epoxidation; rather, there is a
radical rearrangement producing the epoxide. Third, the
Fe(II)−OH2 moiety donates a hydrogen atom to the peroxyl
radical intermediate on C5 for hydroperoxidation but donates a
hydrogen atom to a hydroxide radical for epoxidation, which is
homolytically cleaved from the hydroperoxide. Finally, these
two processes require different substrate rearrangement steps to
abstract a hydrogen atom from the substrate and donate it back
to the intermediate. It is proposed that after abstraction of a
hydrogen atom from C7 and the antarafacial dioxygen attack,
the Fe(II)−OH2 moiety transfers an electron, via long range, to
the peroxyl radical intermediate.33 For epoxidation, the
hydrogen atom is abstracted from C10; however, the Fe(II)−
OH2 moiety is on the same side as the hydroperoxide, leading
to a suprafacial homolytic cleavage of the hydroperoxide
(Figure 2).34 This opens the possibility that the homolytic
cleavage of the hydroperoxide by the Fe(II)−OH2 moiety to
Figure 2. Detailed mechanism of hydroperoxidation and epoxidation [dehydration of 5(S)-HpETE to produce the epoxide]. Hydroperoxidation
proceeds after initial abstraction of the pro-S hydrogen at C7, whereas epoxidation proceeds after abstraction of the pro-R hydrogen at C10.55 The
antarafacial nature of hydroperoxidation is well-known,31,47,79 while a suprafacial arrangement for epoxidation was postulated by Jin et al.34
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produce the epoxide could possibly be achieved via an inner
sphere reduction, directly with the iron center.
In this report, we determine that ATP allosteric activation of
5-LOX promotes both 5(S)-HpETE and LTA4 catalysis by a
similar magnitude. ATP induces hyperbolic activation, allowing
for the determination of Ki, the strength of ATP binding, α, the
change induced in Km, and β, the change induced in Vmax.
Further kinetic investigations into the solvent and viscosity
effects on product formation reveal changes in microscopic rate
constants that promote activation, establishing that ATP is an
allosteric activator of both 5-LOX hydroperoxidation and
epoxidation. Finally, we review the literature on the role of ATP
in inflammation and speculate that the ATP-induced allosteric
activation of 5-LOX in vitro is a potentially relevant modulator
of inflammation in vivo.
■ MATERIALS AND METHODS
Ammonium Sulfate Precipitation of 5-LOX. Recombi-
nant human 5-LOX in a pET21 plasmid was expressed in
Escherichia coli BL21(DE3) cells as described previously.35
Briefly, host cells were grown in LB (100 μg/mL ampicillin) to
an OD of 0.6 at 37 °C, at which time they were induced with
0.25 mM IPTG and cooled to 18 °C for overnight growth.
Cells were then centrifuged at 4700g for 15 min, pelleted into
smaller aliquots at 6200g for 7 min, and snap-frozen in liquid
nitrogen. Frozen cell pellets were resuspended in a nitrogen-
sparged, 4 °C chilled buffer of 50 mM Hepes and 0.1 mM
EDTA (pH 7.5) normalized to an ionic strength of 50 mM with
NaCl (termed buffer A in all subsequent methods). A French
pressure cell press was used to lyse cells at 2000 psi, and the
resulting lysate was centrifuged at 46000g for 25 min.
Ammonium sulfate was added to the supernatant [50% (w/
v)], and the mixture was inverted to mix, centrifuged at 46000g
for 20 min, divided into 200 mg aliquots, and snap-frozen in
liquid nitrogen for long-term storage. When needed for
enzymatic assays, an aliquot was resuspended in nitrogen-
sparged, 4 °C chilled buffer A to a standard concentration and
utilized within 3 h to avoid enzyme degradation caused by the
inherent instability of 5-LOX.
Purification of LOX Hydroperoxide and Hydroxide
Enzymatic Products. High-performance liquid chromatog-
raphy (HPLC) running solutions were made prior to the
experiment. Solution A consisted of 99.9% ACN and 0.1%
acetic acid; solution B consisted of 99.9% H2O and 0.1% acetic
acid. AA was used to generate 5(S)-HpETE. Two liters of 100
μM PUFA substrate in buffer A was reacted with 5-LOX and
the reaction run to completion as monitored by a sample
reaction on a UV−vis spectrometer; the product was promptly
extracted three times with a total volume of dichloromethane of
900 mL, evaporated to dryness, and reconstituted in MeOH for
HPLC purification. Products were injected onto a Higgins
Haisil Semi-Preparative (5 μm, 250 mm × 10 mm) C-18
column with an elution protocol consisting of a 3 mL/min
isocratic mobile phase of 55% solution A and 45% solution B.
Both products were tested using analytical HPLC and liquid
chromatography and tandem mass spectrometry (LC−MS/
MS), demonstrating >90% purity, with the other <10% being
hydrolysis products of the hydroperoxide (5-hydroxides and 5-
ketones), which were found to be inert when reacted with 5-
LOX.
Steady-State Kinetic Measurements. Steady-state kinetic
rates were determined by following the formation of the
conjugated product at 234 nm [ε = 27000 M−1 cm−1 for AA
turnover; ε = 50000 M−1 cm−1 for 5(S)-HpETE turnover] with
a PerkinElmer Lambda 40 UV−vis spectrophotometer at room
temperature (21 °C). All assays were conducted in buffer A. AA
concentrated stock solutions were stored in 95% ethanol and
diluted into buffer so that the total ethanol concentration was
<1%. Fatty acid concentrations were verified by full turnover
with soybean-1 lipoxygenase and quantitating product concen-
tration. Enzymatic reactions were initiated by the addition of
approximately 100−300 nM ammonium sulfate-precipitated
wild-type enzyme. The catalytic activity relative to protein
weight was measured by observing turnover of a 10 μM
solution of AA by the production of 5(S)-HpETE at 234 nm
and was calculated to be ≈0.2 absorbance unit s−1 mg−1, or an
absolute enzymatic activity of ≈60 μmol min−1 mg−1 (not
standardized to metal content). Activities of all wild-type
ammonium sulfate preparations used were within 20% of this
value. Assays were conducted in volumes of 2 mL with
substrate concentrations ranging from 1 to 30 μM and were
constantly stirred with a rotating magnetic bar. Higher substrate
concentrations were avoided to prevent the formation of
micelles, which would alter the free substrate concentration.36
Initial rates (up to the first 20% of the reaction) for each
substrate were fit to the Michaelis−Menten equation using
KaleidaGraph (Synergy) and kinetic parameters calculated.
Calculation of Vmax/Km parameters was conducted by plotting
them as second-order rate constants. All other kinetic
parameters (α, β, and Ki) were calculated from fitting data to
the equations described by Mogul et al.37 and Joshi et al.38 Each
plot comprises data from three or four separate experiments,
and the reported error is the error calculated from nonlinear
regression. Wild-type 5-LOX from the ammonium sulfate
preparation showed no inactivation for the 2 h duration of the
experiment, and no 5(S)-HpETE inhibition was observed for
the initial rates of AA catalysis. Finally, it should be noted that
the ammonium sulfate preparation, without 5-LOX, did not
include any fatty acid substrates or impurity proteins with LOX
activity.
Measurement of the CMC via Isothermal Titration
Calorimetry. CMCs were measured as described by McAuley
et al.39 A MicroCal VP-ITC Calorimeter was used for data
collection. A solution of highly concentrated AA, dissolved in
buffer A, was titrated into a sample cell containing buffer A
only. The final concentration of AA was determined by
quantitating the product concentration after full turnover with
soybean-1 lipoxygenase, and from this, the molar amount of AA
added per injection was extrapolated. Experiments were
repeated three times, and the reported error is the standard
error of the mean (SEM) of each set of measurements.
HPLC Determination of the 5(S)-HETE/5,12-DiHETE
Product Ratio. 5-LOX prepared by ammonium sulfate
precipitation was incubated with 10 μM AA in buffer A at
room temperature (21 °C). Enzymatic reactions were
quenched with 1% (v/v) glacial acetic acid at varied levels of
turnover between 5 and 60%, as determined by UV−vis
spectrophotometry. Products were then extracted with
dichloromethane, reduced with trimethylphosphite, and evapo-
rated to dryness under a nitrogen stream. The products were
purified via HPLC as described above for hydroperoxide
products using a Phenomenex Luna (5 μm, 250 mm × 4.6 mm)
C-18 column and an elution protocol consisting of a 1 mL/min
isocratic mobile phase of 55% solution A and 45% solution B.
The molar amounts of 5(S)-HETE and 5,12-DiHETE were
calculated by the corresponding peak areas determined by
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HPLC and normalized to their respective extinction coefficients
(ε234 = 27000 M
−1 cm−1, and ε280 = 50000 M
−1 cm−1).40,41
Reactions were repeated 12−26 times, and the reported error is
the SEM of each set of measurements.
Structural Determination of 5-LOX-Catalyzed Prod-
ucts by LC−MS/MS. LC−MS/MS running solutions were
made prior to each experiment. Solution A consisted of 99.9%
H2O and 0.1% formic acid; solution B consisted of 99.9% ACN
and 0.1% formic acid. Ammonium sulfate-precipitated 5-LOX
was incubated with 10 μM AA substrate. A 2 mL sample of the
reaction mixture was monitored at 234 nm with a PerkinElmer
Lambda 40 UV−vis spectrophotometer to determine when
complete turnover had been reached. Reactions were quenched
with 1% (v/v) glacial acetic acid, extracted with dichloro-
methane, reduced with trimethylphosphite, evaporated to
dryness, and reconstituted in MeOH. Products were injected
onto a Phenomenex Synergi (4 μm, 150 mm × 4.6 mm) C-18
column attached to a Finnigan LTQ liquid chromatography
mass spectrometer (LC−MS/MS). The elution protocol
consisted of 200 μL/min, with an isocratic mobile phase of
40% solution A and 60% solution B. The corresponding
reduced product ion peak ratio was determined using negative
ion MS/MS (collision energy of 35 eV) with the following
masses: 5(S)-HETE, parent ion at m/z 319 and fragments at
m/z 115, 203, and 129; 5,12-DiHETE, parent ion at m/z 335
and fragments at m/z 317, 273, and 195.42,43
18O Labeling of PUFA Substrates. HPLC running
solutions were made prior to each experiment. Solution A
consisted of 99.9% MeOH and 0.1% acetic acid; solution B
consisted of 99.9% H2O and 0.1% acetic acid. Arachidonoyl
chloride and eicosapentaenoyl chloride (>99%) were purchased
from Nu-Chek Prep, Inc. H2
18O (97%) was purchased from
Cambridge Isotope Laboratories. One molar equivalent of acyl
chloride substrate was reacted with 15 molar equiv of H2
18O in
the presence of dried pyridine for 10 min in a nitrogen-sparged
flask. Lipids were extracted twice with dichloromethane,
evaporated to dryness, and reconstituted in MeOH for HPLC
purification. The sample was injected onto a Higgins Haisil
Semi-Preparative (5 μm, 250 mm × 10 mm) C-18 column and
eluted with an isocratic program of 75% solution A and 25%
solution B. The substrate purity was calculated to be greater
than 99% on an LC−MS/MS, although we measured a range of
18O labeling efficiencies from 57 to 78% in different labeling
experiments. Isotope ratios of labeled to unlabeled PUFA
substrate were used to normalize the data.
Competitive Substrate Capture Investigations of
PUFA and Hydroperoxide Catalysis. LC−MS/MS running
solutions were made prior to each experiment. Solution A
consisted of 99.9% H2O and 0.1% formic acid; solution B
consisted of 99.9% ACN and 0.1% formic acid. Competitive
substrate capture method experiments were performed using a
reaction mixture of labeled PUFA substrate and its respective
hydroperoxide product [[18O]AA/5(S)-HpETE] with a known
molar ratio (1:1) and were initiated with ammonium sulfate-
precipitated 5-LOX in buffer A in the presence or absence of
200 μM ATP. The ratio of the simultaneous product formation
(5,12-[18O]dihydroxides and 5,12-dihydroxides) by 5-LOX was
determined at a total substrate concentration of 1 μM
(substrate limiting conditions). A 2 mL sample of the reaction
mixture was monitored at 234 nm with a PerkinElmer Lambda
40 UV−vis spectrophotometer to determine time points to
achieve ∼5% total substrate consumption (∼0.05 μM).27,44
Reactions were timed and quenched with 1% glacial acetic acid
(v/v), and mixtures were extracted with dichloromethane,
reduced with trimethylphosphite, evaporated to dryness, and
reconstituted in MeOH. Products were injected onto a
Phenomenex Synergi (4 μm, 150 mm × 4.6 mm) C-18 column
attached to a Finnigan LTQ liquid chromatography tandem
mass spectrometer (LC−MS/MS). The elution protocol
consisted of 200 μL/min, with an isocratic mobile phase of
40% solution A and 60% solution B. The corresponding
reduced product ion peak ratio was determined using negative
ion MS/MS (collision energy of 35 eV) with the following
masses: 5,12-DiHETE, parent ion at m/z 335 and fragments at
m/z 317, 273, and 195; 5,12-[18O]DiHETE, parent ion at m/z
337 and fragments at m/z 319, 273, and 197.42 The ratio of the
peak areas for the labeled and unlabeled dihydroxides was then
used to determine the (Vmax/Km)
AA/(Vmax/Km)
5(S)‑HpETE ratio,
modeled after our previous report.44 Reactions were repeated
14−21 times, and the reported error is the SEM of each set of
measurements.
Measurement of Solvent Isotope Effects. Steady-state
kinetics were performed in H2O and
2H2O at room
temperature (21 °C) as previously described to reveal
SIEs.45,46 Reactions were performed in buffer A (H2O, pH
7.5) or in the same buffer made with 2H2O (pH meter reading
of 7.147), and all kinetic parameters were determined as
described above. A Hewlett-Packard diode-array 8453 UV−vis
spectrometer was used to simultaneously observe 5(S)-HpETE
and LTA4 formation and thus determine the SIE for either step
of catalysis.
Measurement of Viscosity Effects. Steady-state kinetics
were performed in the absence or presence of a viscogen
(dextrose) at room temperature (21 °C) to reveal any
diffusion-linked effects on catalysis as previously described.46,48
Maltose, sucrose, ethylene glycol, glycerol, trimethylamine N-
oxide (TMAO), and PEG-8000 were also tested as viscogens,
but all of these inhibited (>50%) enzymatic catalysis and thus
were not further used. Reactions were conducted at different
relative viscosities (ηrel = η/η0, where η0 is the viscosity of H2O
at 20 °C) in 25 mM Hepes and 0.05 mM EDTA (pH 7.5),
normalized to an ionic strength of 25 mM with NaCl. All
Table 1. Steady State Parameters of 5-LOX Hydroperoxidation of AA and Epoxidation of 5(S)-HpETE, with and without ATP
AA hydroperoxidation 5(S)-HpETE epoxidation
[ATP] (μM) relative Vmax
a Km (μM) relative Vmax/Km relative Vmax Km (μM) relative Vmax/Km
0 1.0 ± 0.02 1.9 ± 0.2 0.53 ± 0.05 0.33 ± 0.01 14 ± 1 0.023 ± 0.002
200 4.9 ± 0.3 5.3 ± 0.8 0.90 ± 0.1 1.6 ± 0.09 19 ± 2 0.090 ± 0.01
ATP change 4.9-fold 1.7-fold 4.8-fold 3.9-fold
aThe relative Vmax of 5-LOX (ammonium sulfate-precipitated) and AA, with no cofactors added, is set to 1. All other Vmax values are standardized to
this value and are unitless. Vmax values with 5(S)-HpETE as a substrate were multiplied by 0.54 to account for the difference in extinction coefficients
between HETE (234 nm) and diHETE (280 nm) products. For comparison to other studies, the absolute kinetic activity of all of our wild-type 5-
LOX preparations, without ATP added, was ≈60 μmol min−1 mg−1.
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kinetic parameters were determined as described above in the
absence (ηrel = 1) or presence of 1.873 M dextrose (ηrel = 3).
■ RESULTS AND DISCUSSION
Steady-State Kinetic Dependence on ATP and Ca2+.
Steady-state hydroperoxidation kinetics of AA demonstrated
that the addition of a saturating level of ATP (200 μM)
produced a 4.9-fold increase in Vmax and a 1.7-fold increase in
Vmax/Km. This increase is due to a large increase in Vmax, relative
to a small increase in Km (Table 1), indicating that ATP
increases the rate of product release more so than substrate
capture. These observations are consistent with the ATP
activation reported by Ochi et al. for 5-LOX purified from
guinea pig neutrophils,27 underscoring a similarity between the
ATP activation of human and guinea pig 5-LOX isozymes. It
should be noted that Aharony et al. observed a decrease in Km
upon addition of Ca2+ and ATP, leading to an increase in kcat/
Km (25-fold) larger than what we observed.
30 We infrequently
saw a decrease in Km, as well, but it was only with a small
percentage of our 5-LOX preparations; therefore, we did not
consider it relevant. Interestingly, these infrequent preparations
of 5-LOX, which demonstrated a decrease in Km, also exhibited
substrate inhibition and manifested artificially lower Km values.
This substrate inhibition was not due to a change in the critical
micelle concentration (CMC) for AA because the substrate
concentrations used were well below the CMC values [CMC =
43 ± 3 μM (no ATP) and 52 ± 1 μM (200 μM ATP)], as
measured by isothermal titration calorimetry. In addition, it was
confirmed with our 5-LOX preparation that calcium was not
required for ATP activation (data not shown), as previously
reported with recombinant human 5-LOX, obtained from
insect cell expression.31,49 However, we did notice that calcium
slightly diminished the level of ATP activation (∼10%), but the
cause of this small reduction in the level of activation is unclear.
1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC), with
and without Ca2+ and/or Mg2+, also showed no observable
kinetic effect on ATP activation. Furthermore, DMPC hindered
accurate absorption detection because of its high background
absorption, and thus, it was not included in further experiments
(data not shown).
Steady-state epoxidation kinetics of 5(S)-HpETE demon-
strated a 3-fold smaller Vmax and a 23-fold smaller Vmax/Km,
compared to those for hydroperoxidation of AA (Table 1).
These results highlight a prominent difference between AA and
5(S)-HpETE in their rates of substrate capture and suggest that
LTA4 formation could occur more readily from sequential steps
of hydroperoxidation and then epoxidation with AA, as has
been previously observed.40,50 The addition of a saturating level
of ATP (200 μM) produced a 4.8-fold increase in Vmax with
5(S)-HpETE as the substrate, which was the same magnitude
of activation seen for AA hydroperoxidation (Table 1). In
contrast, ATP induced a 3.9-fold increase in Vmax/Km, which
indicates a 2-fold greater ATP-induced activation of Vmax/Km
for 5(S)-HpETE epoxidation than for AA hydroperoxidation
(1.7-fold). These data demonstrate a distinction in the ATP
activation mechanism for hydroperoxidation and epoxidation,
and therefore, more extensive investigations were used to
understand ATP activation in more detail.
Effect of ATP-Induced Activation on Hydroperoxide
Retention and Epoxide Formation. As described above,
ATP activates both AA hydroperoxidation and 5(S)-HpETE
epoxidation. However, it is unclear if the epoxidation reaction
affects the rate of hydroperoxidation, because of the
consumption of the hydroperoxidation product, 5(S)-HpETE,
and/or production of the 5,6-epoxide, LTA4. To investigate this
possibility, a diode-array UV−vis spectrophotometer was used
to observe the formation of both 5(S)-HpETE (234 nm) and
LTA4 (280 nm) simultaneously from 0 to 20% product
formation and determine if the slight increase in the 5(S)-
HpETE concentration could affect the rate of hydroperoxide
formation. The LTA4/5(S)-HpETE ratio of products (the
efficiency of epoxide formation) was calculated throughout the
reaction and observed to remain constant up to 20% product
formation [LTA4/5(S)-HpETE ratio of 0.161 ± 0.004 (Figure
3)]. With the addition of 200 μM ATP, this value increased to a
constant value of 0.247 ± 0.005 (Figure 3) and matched the
value determined for rat PMNL 5-LOX.40 In addition, 5(S)-
HETE and 5,12-DiHETE concentrations were quantified via
HPLC and comparable product ratios were observed [0.19 ±
0.02 (no ATP) and 0.25 ± 0.02 (200 μM ATP)], confirming
the accuracy of the dual-wavelength assay (Figure 3). These
data indicate that the consumption of 5(S)-HpETE, and the
subsequent production of the 5,6-epoxide, does not affect the
relative rates of hydroperoxidation and epoxidation.
Hyperbolic Activation of 5-LOX by ATP. To compare
the allosteric effect of ATP activation for AA hydroperoxidation
and 5(S)-HpETE epoxidation in more detail, extensive
allosteric titrations were performed (Table 2). From the data,
it was observed that 5-LOX and AA exhibited a hyperbolic
response to increasing amounts of ATP with an increase in
Km(app) from 1.9 ± 0.2 to 5.3 ± 0.8 μM and an increase in
Vmax/Km(app) from 0.53 ± 0.05 to 0.9 ± 0.1. The saturation
behavior of Km(app) and Vmax/Km, with AA as the substrate, is
indicative of hyperbolic activation (i.e., partial activation).
Figure 3. Effect of 200 μM ATP on the efficiency of epoxide
formation. [LTA4]/[5(S)-HpETE] turnover ratio from 10 μM AA
substrate as measured by HPLC and UV−vis spectrophotometry.
[LTA4] was measured at 280 nm and [5(S)-HpETE] at 234 nm, and
both were normalized to their respective extinction coefficients. The
absolute kinetic activity of wild-type 5-LOX ammonium sulfate
preparations was ≈60 μmol min−1 mg−1.
Table 2. Kinetic Parameters for ATP-Induced Activation of
5-LOXa
substrate α β β/α Ki (μM)
AA 3.0 ± 0.4 5.4 ± 0.08 1.8 ± 0.2 8.0 ± 6
5(S)-HpETE 1.6 ± 0.08 5.1 ± 0.1 3.3 ± 0.2 12 ± 5
aHyperbolic fit parameters of 5-LOX with ATP and AA or 5(S)-
HpETE as substrates.
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Similar hyperbolic allostery has been observed for other LOX
isozymes with different allosteric regulators, such as soybean
15-LOX-1 with oleyl sulfate37 and human 15-LOX-2 with
13(S)-HODE.38 These data indicate the presence of an
allosteric binding site in 5-LOX that affects the catalysis by
changing the microscopic rate constants of 5-LOX, as described
in Scheme 1. From Scheme 1, eqs 1−4 allow for the
determination of Ki, the strength of binding, α, the change in
Km, β, the change in Vmax, and β/α, the change in Vmax/Km.
ν α β α
α β α
= × + +
× + × + +
K V K K
V K K
1/ ( / ) [([I] )/( [I] )]
1/[S] 1/ [([I] )/( [I] )]
m max i i
max i i (1)
α α= + +K K K K(app) [([I] )/([I] )]m m i i (2)
α β α= × + +V K V K K K/ (app) ( / ) [( [I] )/([I] )]max m max m i i
(3)
β α α= + +V V K K(app) [( [I] )/([I] )]max max i i (4)
A plot of Km(app) versus ATP concentration, with AA as the
substrate (Figure 4), yielded an α of 3.0 ± 0.4 and a Ki of 8 ± 6
μM, when fit with eq 2 (Table 2). The values of α and Ki were
then utilized in eq 3 and fit to the Vmax/Km data, which yielded
a β of 5.5 ± 0.5. The value of β was also determined from the
Vmax data (fit with eq 4 and the values of α and Ki given above),
which yielded a β of 5.4 ± 0.08 (Figure 5) and matched well
with the β value from the Vmax/Km plot. These values indicate
mixed hyperbolic allostery [α > 1 (K-type inhibition), and β > 1
(V-type activation)],51 with the majority of the kinetic change
being seen in the value of Vmax. This larger Vmax change is best
observed by considering the Vmax/Km value, which is greater
than 1 (β/α = 1.8 ± 0.2) and indicates Vmax/Km allosteric
activation. These hyperbolic data suggest the formation of a
catalytically active ternary complex (A·E·S) between 5-LOX
and ATP and are consistent with the previous finding of an
allosteric site in 5-LOX.31,52 The data are also consistent with
what was observed at saturating ATP concentrations (listed in
Table 1).
Similar ATP titration experiments were also performed with
5(S)-HpETE as the substrate, which showed an α value of 1.56
± 0.08 (K-type inhibition) and a Ki value of 12 ± 5 μM (Table
2), from the Km(app) plot (Figure 6). The α value was half the
α value for AA activation, indicative of a weaker ATP allosteric
effect on Km with 5(S)-HpETE as the substrate. However, the
Ki value was comparable to that of AA activation, indicating
similar ATP binding affinities and most likely the same ATP
binding site for both hydroperoxidation and epoxidation. The β
value was determined to be 5.1 ± 0.1 (Figure 7), which is V-
type activation, similar to that seen for AA. The β/α ratio is
nearly 2-fold greater for 5(S)-HpETE (3.3 ± 0.2) than for AA
(1.8 ± 0.2), indicating that ATP activates the rate of substrate
capture for 5(S)-HpETE more so than AA. These results agree
with our kinetic results at saturating ATP concentrations
(Table 1), suggesting that the allosteric effect caused by ATP
binding has largely similar consequences for both the
Scheme 1. Kinetic Scheme for Allosteric Activation of 5-
LOXa
a5-LOX catalysis including hyperbolic partial activation induced by
ATP. Similar hyperbolic allostery has been observed for other LOX
isozymes with different allosteric regulators, such as soybean 15-LOX-
1 with oleyl sulfate37 and human 15-LOX-2 with 13(S)-HODE.38
Figure 4. Effect of ATP on the Km(app) of 5-LOX with the AA
substrate. The data are fit to eq 2 (Scheme 1), where Km = 1.9 μM. α
and Ki were determined to be 3.0 ± 0.4 and 8.0 ± 6 μM, respectively.
Figure 5. Effect of ATP on the Vmax(app) of 5-LOX with the AA
substrate. The data are fit to eq 4 (Scheme 1) with a Km of 1.9 μM, an
α of 3, and a Ki of 8, where β was determined to be 5.4 ± 0.08.
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hydroperoxidation of AA and the epoxidation of 5(S)-HpETE,
but with subtle differences in magnitude.
Endogenous and Exogenous Rates of Epoxide
Formation. As mentioned above, 5-LOX can produce LTA4
from AA sequentially [first producing 5(S)-HpETE and then
LTA4] or from 5(S)-HpETE directly. To improve our
understanding of the kinetic differences between endogenous
5(S)-HpETE epoxidation (generated in situ from AA) and
exogenous 5(S)-HpETE epoxidation [binding 5(S)-HpETE
directly], steady-state experiments with AA and 5(S)-HpETE as
substrates were performed by indirectly observing epoxide
formation from its decomposition product at 280 nm (5,12-
diHETE). From Table 3, it is observed that the Vmax values of
epoxidation for both AA and 5(S)-HpETE were the same. This
implies that hydrogen abstraction is a dominant rate-limiting
step for Vmax of epoxidation because 5-LOX abstracts the same
hydrogen atom from 5(S)-HpETE for epoxidation (C10),
regardless of whether the 5(S)-HpETE is endogenous
(generated in situ) or exogenous (bound directly) (Figure 2).
In contrast to the Vmax data, the Vmax/Km for epoxidation of
endogenous 5(S)-HpETE was found to be 9-fold larger than
the Vmax/Km for epoxidation of exogenous 5(S)-HpETE.
Considering that both endogenous and exogenous 5(S)-
HpETE share the same hydrogen abstraction step, these data
indicate there is a difference in their rate-limiting steps prior to
hydrogen atom abstraction. A saturating level of ATP (200
μM) activated the Vmax and the Vmax/Km for both endogenous
5(S)-HpETE and exogenous 5(S)-HpETE epoxidation, as
would be expected; however, there were slight differences.
ATP increased the Vmax of endogenous 5(S)-HpETE 6.5-fold,
relative to 4.8-fold for exogenous 5(S)-HpETE. ATP increased
the Vmax/Km of endogenous 5(S)-HpETE 2.4-fold, relative to
3.9-fold for exogenous 5(S)-HpETE. The overall similarity in
the ATP activation of endogenous and exogenous 5(S)-HpETE
is indicative of similar mechanisms. However, the slight
differences in ATP activation between endogenous and
exogenous 5(S)-HpETE could be due to slight differences in
their microscopic rate constants or possibly experimental error.
Competitive Substrate Capture Investigations of AA
and 5(S)-HpETE Catalysis. To further investigate the kinetics
of AA and 5(S)-HpETE catalysis, a competitive substrate
capture experiment was performed with a mixture of [18O]AA
(0.5 μM) and unlabeled 5(S)-HpETE (0.5 μM). The results
without ATP demonstrated that the amount of 5,12-DiHETEs
produced from [18O]AA was larger than the amounts produced
from exogenous 5(S)-HpETE, with a measured (Vmax/Km)
AA/
(Vmax/Km)
5(S)‑HpETE epoxide efficiency ratio of 1.8 ± 0.06.
These results confirm the steady-state results (vide supra) that
5-LOX is more likely to retain the nascent 5(S)-HpETE in its
active site than to bind exogenous 5(S)-HpETE to generate the
epoxide. The competitive experiment was repeated with a
saturating level of ATP (200 μM), and the (Vmax/Km)
AA/(Vmax/
Km)
5(S)‑HpETE ratio increased to 2.2 ± 0.06, indicating an
increase in the epoxide efficiency of AA conversion, relative to
that of 5(S)-HpETE conversion. This is in contrast to the
steady-state (Vmax/Km)
AA/(Vmax/Km)
5(S)‑HpETE ratio, which not
only is larger than the competitive ratio (ratio of 8.6) but also
decreases with the addition of ATP (ratio of 6.4). These
differences between the two methods could be due to the fact
that the competitive measurements were performed with both
substrates present while the steady-state experiments included
only one substrate at a time. As seen previously for 15-LOX-1
and 15-LOX-2,37,38 differences between competitive and
steady-state measurements can be indicative of allosteric effects
by either the substrate or product. Therefore, while these data
confirm that the majority of LTA4 produced by 5-LOX is made
from AA and not 5(S)-HpETE, additional experiments are
required to investigate why the steady-state and competitive
methods do not correlate. For comparison, Puustinen et al.
observed a (Vmax/Km)
AA/(Vmax/Km)
5(S)‑HpETE epoxide efficiency
ratio of approximately 3.2 for 5-LOX from the human leukocyte
homogenate, with ATP being present,50 while Wiseman et al.
measured a (Vmax/Km)
AA/(Vmax/Km)
5(S)‑HpETE ratio of 32 ± 1
Figure 6. Effect of ATP on the Km(app) of 5-LOX with the 5(S)-
HpETE substrate. The data are fit to eq 2 (Scheme 1), with a Km of 14
μM. α and Ki were determined to be 1.6 ± 0.08 and 12 ± 5 μM,
respectively.
Figure 7. Effect of ATP on the Vmax(app) of 5-LOX with the 5(S)-
HpETE substrate. The data are fit to eq 4 (Scheme 1) with a Km of 14
μM, an α of 1.6, and a Ki of 12, where β was determined to be 5.1 ±
0.1.
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for 5-LOX from rat PMNLs in the presence of ATP,40
indicating possible differences between species.
Solvent Effects of the Hydroperoxidation and
Epoxidation Kinetics. The mechanism of hydroperoxidation
for soybean 15-LOX,47,53 human 12-LOX,45,46 human 15-LOX-
1,45,46 and human 15-LOX-248 has been shown previously to
manifest multiple rate-limiting steps, defined by substrate
diffusion, hydrogen bond rearrangement, and hydrogen atom
abstraction. However, the mechanisms employed by 5-LOX for
hydroperoxidation and epoxidation are less well under-
stood.30,40 The 5-LOX mechanism for hydroperoxidation has
historically been assumed to be similar to that of other
lipoxygenases,54 but little experimental evidence has been
found. The epoxidation reaction is also proposed to proceed
through a hydrogen atom abstraction mechanism, similar to
that of hydroperoxidation,34 which is supported by a large
primary kinetic isotope effect of >10,6,55,56 and inhibition of
LTA4 formation by reductive inhibitors.
4 On the basis of the
data described above, a scheme has been generated to represent
the general steps of hydroperoxidation and epoxidation
(Scheme 2). The scheme includes rearrangement steps (k3
and k7) and hydrogen atom abstraction steps (k5 and k11) for
both hydroperoxidation and epoxidation, respectively. It should
be noted that k11 includes both abstraction and product release.
With respect to ATP activation, previous work did not
determine if molecular steps in the reaction coordinate for
either hydroperoxidation or epoxidation are accelerated (Figure
2) or if activation proceeds through an alternative process that
does not affect the catalytic mechanism, such as protein
stabilization.31
In the work presented here, hydroperoxidation kinetic
studies of AA in the absence of ATP revealed a normal solvent
isotope effect (SIE) for Vmax[AA] (1.8 ± 0.2) and an inverse
SIE for Vmax/Km[AA] (0.66 ± 0.3) (Table 4). Under ATP
activation (200 μM ATP), the normal SIE increased for
Vmax[AA] to 3.1 ± 0.6, while the inverse SIE for Vmax/Km[AA]
changed to a normal SIE of 1.8 ± 0.6, demonstrating that ATP
affects the molecular mechanisms of both substrate capture and
product release. In general, SIE values of 2−3 typically
correspond to general acid/base catalysis, while the extent of
solvation of catalytic bridges ranges from 1.5 to 4.57,58 Previous
studies of LOX isozymes45−48,53 attribute their observed SIE
results to a solvent-dependent hydrogen transfer from multiple
hydrogen bond rearrangements, presumably because of an
enzymatic conformational change upon substrate binding.
Interestingly, although all four LOX isozymes manifested
SIEs, their magnitude and temperature dependence varied,
indicating subtle differences in their rate-limiting steps. For 5-
LOX, the magnitude of the normal SIE for Vmax[AA], with and
without ATP added, indicates a hydrogen bond rearrangement
step (i.e., general conformational change), similar to that seen
for other LOX isozymes. The increase in the normal Vmax SIE
value, with addition of ATP, indicates that the hydrogen bond
rearrangement step becomes more rate-limiting with added
ATP and that the activation of 5-LOX by ATP is in part due to
a change in its microscopic rate constants, such as increasing
the rate of hydrogen atom abstraction (vide inf ra). It should be
noted that lower values of SIE (<1.5) are typically ascribed to
proton transfer coupled to heavy atom motion in the transition
state59 or to increased viscosity of D2O relative to H2O.
60
These are unlikely explanations for our data, given their larger
SIE values.
In contrast to the Vmax SIE, the Vmax/Km of AA manifests an
inverse SIE without ATP (SIE = 0.66 ± 0.3), which becomes a
normal SIE (SIE = 1.80 ± 0.61) upon addition of ATP.
Previously, our laboratory observed inverse SIE values for both
Vmax and Vmax/Km for a soybean 15-LOX mutant
61 and wild-
type 15-LOX-2,48 which was ascribed to the participation of a
ferric−hydroxide moiety in the abstraction of the hydrogen
atom. It is possible that the observed inverse SIE for 5-LOX
with AA is also due to the ferric−hydroxide moiety; however,
because of its large error, it is difficult to state this with
certainty. Nonetheless, the change to a normal SIE upon
Table 3. Steady State Parameters of 5-LOX Epoxidation of AA (Endogenous) and Epoxidation of 5(S)-HpETE (Exogenous),
with and without ATP
AA epoxidation (endogenous) 5(S)-HpETE epoxidation (exogenous)
[ATP] (μM) relative Vmax
a Km (μM) relative Vmax/Km relative Vmax Km (μM) relative Vmax/Km
0 0.31 ± 0.01 1.6 ± 0.3 0.18 ± 0.04 0.33 ± 0.01 14 ± 1 0.023 ± 0.002
200 2.0 ± 0.1 4.5 ± 0.7 0.44 ± 0.06 1.6 ± 0.09 19 ± 2 0.090 ± 0.01
ATP change 6.5-fold 2.4-fold 4.8-fold 3.9-fold
aThe Vmax of 5-LOX epoxidation of AA (endogenous), with no cofactors added, is normalized to the Vmax of 5-LOX hydroperoxidation of AA (Table
1). The values for 5(S)-HpETE epoxidation (exogenous) from Table 1 are listed again for clarity. For comparison to other studies, the absolute
kinetic activity of all of our wild-type 5-LOX preparations, without ATP added, was ≈ 60 μmol/min/mg.
Scheme 2. Kinetic Scheme for 5-LOX Hydroperoxidation
and Epoxidation (Dehydration)a
a5-LOX catalysis proceeds with hydroperoxidation of AA to 5(S)-
HpETE and either product release or subsequent epoxidation
(dehydration) to LTA4. This is based on a scheme originally published
by Wiseman et al.40 The final step (k11) includes both chemical and
release steps.
Table 4. Solvent Isotope Effect (SIE) Values for
Hydroperoxidation of AA and Epoxidiation of 5(S)-HpETE
AA hydroperoxidation
(234 nm)
5(S)-HpETE epoxidation
(280 nm)
[ATP] (μM) Vmax SIE Vmax/Km SIE Vmax SIE Vmax/Km SIE
0 1.8 ± 0.2 0.66 ± 0.3 0.81 ± 0.1 0.49 ± 0.09
200 3.1 ± 0.6 1.8 ± 0.6 2.6 ± 0.3 1.2 ± 0.2
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addition of ATP is significant and indicates a shift in the nature
of the rate-determining step, possibly from a dependence on
hydrogen atom abstraction by the ferric hydroxide to a
dependence on hydrogen bond rearrangement. It should be
noted that Vmax/Km includes the bimolecular encounter of
substrate and enzyme, up to the first irreversible step (hydrogen
atom abstraction), but Vmax includes steps after enzyme
substrate complex formation, and therefore, the SIE observed
for Vmax and Vmax/Km could be from the same step or from
different steps.
Identical solvent dependence studies, with 5(S)-HpETE as a
substrate, were also performed (Table 4). Interestingly, the Vmax
SIE for 5(S)-HpETE epoxidation (Vmax SIE = 0.81 ± 0.1) was
markedly different from that for AA (Vmax SIE = 1.8 ± 0.2).
This result clearly demonstrates an inverse SIE for 5(S)-
HpETE epoxidation and indicates the participation of the
Fe(III)−OH moiety in the hydrogen abstraction mechanism as
a contributor to the rate-limiting step (vide inf ra). Adding ATP,
with 5(S)-HpETE as the substrate, increased the epoxidation
SIE to 2.6 ± 0.3. This increase in SIE is nearly identical to that
with AA as a substrate, showing that both processes, AA
hydroperoxidation and 5(S)-HpETE epoxidation, display an
ATP-induced increase in SIE, suggesting a shift in their rate-
limiting step to being more dependent on hydrogen bond
rearrangement and less on the hydrogen atom abstraction by
the Fe(III)−OH moiety.
For the Vmax/Km data, the 5(S)-HpETE epoxidation SIE is
0.49 ± 0.09. This value is similar to that seen previously for AA
hydroperoxidation (SIE = 0.66 ± 0.3) and indicates that the
rate-limiting step of Vmax/Km, for both AA hydroperoxidation
and 5(S)-HpETE epoxidation, is dominated by the hydrogen
atom abstraction of the Fe(III)−OH moiety. After addition of
ATP, the 5(S)-HpETE epoxidation SIE increased to 1.2 ± 0.2,
similar to the increase seen for the AA hydroperoxidation (SIE
= 1.8 ± 0.6). This is consistent with a change in the rate-
limiting step to being more dependent on hydrogen bond
rearrangement and less on hydrogen atom abstraction.
Considering that ATP activates both hydroperoxidation and
epoxidation to a similar extent and in a similar manner, it is
reasonable that for both processes, ATP increases the rate of
hydrogen atom abstraction and hence lowers its contribution to
the rate-limiting step.
In summary, the SIE results described above indicate that
both hydrogen atom abstraction and hydrogen bond rearrange-
ment are important rate-limiting steps for AA hydroperox-
idation and 5(S)-HpETE epoxidation. However, the impor-
tance of hydrogen atom abstraction in the rate-limiting step
increases for epoxidation and could explain the rate for
epoxidation being slower than that for hydroperoxidation (vide
inf ra). In addition, the ATP-induced allosteric effect changes
the solvent dependency of the rate-limiting step for both
hydroperoxidation and epoxidation, which cannot be explained
by an ATP-induced stabilization of the 5-LOX protein
structure.31 Rather, the changes in SIE with the addition of
ATP suggest a shift in the rate-limiting step toward hydrogen
bond rearrangement relative to hydrogen atom abstraction for
both hydroperoxidation and epoxidation. Unfortunately, it
could not determine if ATP affects hydrogen atom abstraction
directly, because isotopically labeled AA is not readily available.
Viscosity Effects of the Hydroperoxidation and
Epoxidation Kinetics. To further probe the nature of the
rate-limiting step, viscosity experiments in dextrose (η/η° = 1
and 3) were performed in the absence and presence of 200 μM
ATP (Table 5). The (Vmax/Km°)/(Vmax/Km) for AA substrate
was calculated to be 1.5 ± 0.3 without ATP and 1.2 ± 0.2 with
ATP, where Vmax/Km° has an η/η° of 1 and Vmax/Km has an η/
η° of 3. These data indicate that the rate of substrate capture is
not diffusion-controlled, with or without ATP. However, it is
interesting to note that Vmax°/Vmax increased from 1.0 ± 0.1 to
1.6 ± 0.2 upon ATP activation. Because there is no viscosity
effect seen for Vmax/Km, these data are best explained by
decreased translational diffusion rates and/or conformational
changes upon substrate binding,62−64 the latter being consistent
with the SIE results.
In contrast to the viscosity effect with AA as the substrate, an
inverse viscosity effect can be seen on Vmax/Km with 5(S)-
HpETE as the substrate [(Vmax/Km°)/(Vmax/Km) = 0.65 ± 0.1].
Considering there is no viscosity effect observed under the
same conditions for the faster reaction of 5-LOX and AA, the
inverse viscosity effect on Vmax/Km with 5(S)-HpETE appears
to arise through a different mechanism. A change in the
dielectric environment65 could result in an inverse effect, but
the dielectric constant of water (∼80) is reduced by only 10%
with the addition of 30% by mass dextrose.66 Moreover, the
finding that this inverse viscosity effect is removed by the
addition of ATP also suggests dielectric constants are not
inducing the effect. Experiments with PEG-8000 were
attempted to confirm that the viscosity effect is independent
of a change in dielectric constants; however, PEG was observed
to inactivate 5-LOX, and thus, no conclusion was possible (data
not shown). The only other hypothesis for the inverse viscosity
effect on (Vmax/Km°)/(Vmax/Km) is due to a partially rate-
determining conformational change during catalysis,60 which is
supported by the fact that the SIE results also indicate a
conformational change. Upon addition of ATP, the (Vmax/
Km°)/(Vmax/Km) viscosity effect with 5(S)-HpETE as a
substrate becomes 1.6 ± 0.4. Given the slow rate of 5(S)-
HpETE epoxidation relative to AA hydroperoxidation, and the
fact that no viscosity effect was seen for AA hydroperoxidation,
the normal viscosity effect on 5(S)-HpETE Vmax/Km induced
by ATP is most likely not due to a diffusion-controlled
mechanism. Therefore, the small (Vmax/Km°)/(Vmax/Km)
viscosity effect with ATP may possibly be due to a
conformational change during catalysis. The Vmax°/Vmax
viscosity effect did not change upon addition of ATP (1.0 ±
0.2 to 1.3 ± 0.2), indicating diffusion is not rate-limiting, with
or without ATP. It should be noted that only dextrose allowed
for viscosity measurements. It is typical of LOX isozymes to be
sensitive to high concentrations of viscogens;47,60 however, the
data would engender more confidence if another viscogen
could manifest similar results. Future experiments are needed
to probe the nature of the viscogen effect further.
Table 5. Viscosity Effect Values for Hydroperoxidation of AA and Epoxidiation of 5(S)-HpETE
AA hydroperoxidation (234 nm) 5(S)-HpETE epoxidation (280 nm)
[ATP] (μM) Vmax°/Vmax (Vmax/Km°)/(Vmax/Km) Vmax°/Vmax (Vmax/Km°)/(Vmax/Km)
0 1.0 ± 0.1 1.5 ± 0.3 1.0 ± 0.2 0.65 ± 0.1
200 1.6 ± 0.2 1.2 ± 0.2 1.3 ± 0.2 1.6 ± 0.4
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■ CONCLUSION
It has been known in the literature for many years that 5-LOX
has two catalytic functions, hydroperoxidation of AA (oxidation
of PUFA) and epoxidation of 5(S)-HpETE (dehydration of
hydroperoxide), but a detailed kinetic investigation comparing
these two processes has never been undertaken. In the work
presented here, we demonstrate that the Vmax of 5(S)-HpETE
epoxidation is 3-fold slower than the Vmax of AA hydro-
peroxidation and that the corresponding Vmax/Km is 23-fold
slower, indicating that both the rate of substrate capture and the
rate of product release are less efficient for epoxidation than for
hydroperoxidation. These rate differences could be due to the
fact that the hydrogen atom is abstracted from C7 for
hydroperoxidation of AA, as opposed to C10 for epoxidation
of 5(S)-HpETE, as discussed in the introductory section
(Figure 2). This hypothesis is supported by the SIE results,
which indicate a stronger dependence on hydrogen atom
abstraction for epoxidation than hydroperoxidation. In addition,
if one measures the rate of epoxidation of endogenous and
exogenous 5(S)-HpETE [i.e., 5(S)-HpETE generated in situ
from AA and 5(S)-HpETE bound directly, respectively], one
observes that their Vmax values are the same. However, there is a
9-fold larger Vmax/Km for endogenous 5(S)-HpETE than for
5(S)-HpETE epoxidation. Considering that the Vmax is the
same for both processes, the rate difference appears to be due
to a difference in a microscopic rate constant before hydrogen
atom abstraction, possibly a structural rearrangement [k3 for
hydroperoxidation of AA and k7 for epoxidation of 5(S)-
HpETE]. In the recently determined crystal structure for
human 5-LOX, a unique FY cork feature is observed that blocks
one possible entrance to the active site.32 We hypothesize that a
difference in the rearrangement of the FY cork could be the
source of the kinetic difference between AA and 5(S)-HpETE
binding, highlighting future research directions for studying the
epoxidation mechanism. Importantly, these results indicate that
5-LOX has overcome a significant catalytic barrier of
epoxidation by retaining the 5(S)-HpETE in its active site for
sequential epoxidation and not binding free 5(S)-HpETE
directly.
Along this same line of investigation, it was determined that
ATP activates the Vmax of AA (4.9-fold) and the Vmax of 5(S)-
HpETE by a similar degree (4.8-fold). However, ATP activates
the Vmax/Km to a lesser extent [1.7-fold for AA and 3.9-fold for
5(S)-HpETE], indicating ATP affects substrate capture and
product release differently. Further titration of 5-LOX with
ATP yielded hyperbolic kinetic parameters supporting the
similarity between the activation of hydroperoxidation and
epoxidation. Both processes displayed similar V-type activation,
but the extent of K-type inhibition was greater with AA as the
substrate, resulting in a greater activation for Vmax/Km for 5(S)-
HpETE.
Inverse Vmax/Km SIE values observed for 5-LOX indicate the
rate-limiting step for substrate capture is dominated by the
hydrogen atom abstraction by the Fe(III)−OH moiety (k5 for
hydroperoxidation and k11 for epoxidation). However, ATP
shifts the inverse Vmax/Km SIE for both AA and 5(S)-HpETE to
normal SIE values, indicating an increased dependence of the
rate-limiting step on solvent. Given the previous assignment of
the SIE to hydrogen bond rearrangement for other LOX
isozymes,45−48,53 it appears that addition of ATP increases the
dependence of the rate-limiting step on hydrogen bond
rearrangement (k3 and k7) relative to hydrogen atom
abstraction (k5 and k11). Considering that neither mechanism
is limited by substrate diffusion but both substrate capture rates
are limited by hydrogen atom abstraction (inverse SIE), it
appears that the 23-fold faster rate for hydroperoxidation is due
to an increased rate of hydrogen atom abstraction compared to
the rate of epoxidation. In addition, it appears that ATP
increases the rate of hydrogen atom abstraction, such that its
contribution to the rate-limiting step is decreased. This
hypothesis is remarkable because the position of the abstracted
hydrogen atom for hydroperoxidation and epoxidation is
distinct (C7 and C10, respectively), and the overall structure
of the substrates is also distinct [AA vs 5(S)-HpETE].
However, subtle changes in the positioning of the abstracted
hydrogen relative to the Fe(III)−OH moiety have an effect on
LOX rates,47,53 and therefore, substrate differences and/or
addition of ATP would likely affect the rate of 5-LOX. We are
currently investigating the molecular mechanism of ATP
activation further to gain molecular insight into how the rate
of hydrogen atom abstraction is increased.
With respect to the larger implications of these ATP results,
5-LOX has a unique role in the inflammatory response by
catalyzing the formation of potent pro- and anti-inflammatory
molecules, and as such, the cell has devised several strategies for
regulating its control.8,19,21,31,52,67 Along these lines, we note
that ATP has a well-established role as an upregulated mediator
in inflammation68−70 and that extracellular ATP is measured at
elevated levels for patients suffering from inflammatory
diseases, such as chronic obstructive pulmonary disease
(COPD) and emphysema, which are known to involve
leukotrienes as causal factors in their pathology.71−76
Lommatzsch et al. recently established that ATP concentrations
in bronchoalveolar lavage fluid increased from <10 μM in a
control group of patients to >300 μM in patients with
increasing stages of COPD. They also presented in vitro results
suggesting that increasing concentrations of extracellular ATP,
from 1 to 100 μM, increased the chemotactic index of human
neutrophils, an effect that saturated and resisted any further
changes even when probed with 1000 μM extracellular ATP.72
While a direct link to 5-LOX activity was not tested, we note
that these results correlate with our measured Ki of ATP-
induced activation for 5-LOX (∼10 μM), suggesting a possible
connection between the increasing chemotactic index and ATP-
induced activation of 5-LOX in disease. There is also evidence
of intracellular compartmentalization of ATP itself up to low
millimolar concentrations77 and for high micromolar amounts
of ATP being released extracellularly from HEK293 and ACN
neuroblastoma cells through nonlytic ATP release,78 further
demonstrating that the concentration of ATP necessary for
ATP-induced activation is biologically relevant. We reason that
these divergent lines of evidence could suggest that the ATP-
induced allosteric effect of 5-LOX we have characterized herein
may be another biologically relevant form of 5-LOX regulation
through which inflammation control can be modulated. The
distinction between extracellular and intracellular ATP is an
important one, and while ATP is thought to be released from
neutrophils,74 5-LOX activation would still require an elevated
intracellular ATP concentration prior to release. The critical
question is whether the ATP concentration in the 5-LOX-
localized cellular compartment is changing as the experiments
described above predict, suggesting future directions for in vivo
research.
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